Illumina Inc.: Why This DNA Giant Just Got Way More Interesting for You

FierceBiotechChutes & Ladders—Perrigo CEO ousted over ‘personal conduct’

Endpoints NewsWuXi AppTec sues Pentagon in challenge over inclusion on Chinese military list

Endpoints NewsGSK took advantage of ASCO dip to get discount on Nuvalent

Endpoints NewsNovo's M&A leader leaves for Forbion; Perrigo CEO's 'personal conduct' issues led to resignation

Clinical OMICsA Spoonful of Hydrogel Keeps the Medicine in Place

Endpoints NewsSciwind has two Western partners for its obesity drug, but is open to more

FierceBiotechNovartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover

LabiotechAdvancing corticosteroids and hormonal therapies for supply and scale

FierceBiotech‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff

Lonza NewsSmall-Molecule CDMO Outlook: What Lies Ahead - DCAT Value Chain Insights

Clinical OMICsPioneering Innovation in Transplant Diagnostics

FierceBiotechRoche nabs EU approval on label expansions for companion dx platform